Company Overview
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Recent Developments
- Dec 2025 Revenue of $559.00K (-98.7% YoY); net profit $-88.61M.
- Trailing 12 Months Year-on-year growth — revenue +197.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -70.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -70.45% |
| 1 Year: | 197.20% |
Stock Price Performance
| 1 Year: | +134.02% |
| 6 Months: | +121.16% |
| 3 Months: | +119.74% |
| 1 Month: | +14.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -70.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLN Silence Therapeutics plc PHARMA | 13.69 | -10.61 | $850.89M | 0.00% | -76.17% | -90.41% | -70.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.70M | 756.00K | 1.50M | - | 142.00K | 224.00K | 159.00K | 34.00K | 422.00K |
| Cost of Revenue | - | - | - | - | 54.00K | 85.00K | 64.00K | 12.00K | 11.00K |
| Gross Profit | 12.90M | -2.58M | -2.14M | - | 88.00K | 139.00K | 95.00K | 22.00K | 411.00K |
| Operating Expenses | - | - | - | - | 28.50M | 22.78M | 26.34M | 12.48M | 16.15M |
| Operating Income | -5.58M | -23.39M | -30.00M | - | -28.41M | -22.64M | -26.24M | -12.46M | -15.74M |
| EBITDA | - | - | - | - | -28.27M | -22.49M | -26.09M | -12.35M | -15.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -28.53M | -27.34M | -20.96M | -11.77M | -14.96M |
| Tax Provision | - | - | - | - | 0 | 10.00K | 1.00K | 0 | 0 |
| Net Income | -2.31M | -19.75M | -35.54M | - | -28.53M | -27.35M | -20.96M | -11.77M | -14.96M |
| Diluted EPS | -0.02 | -0.14 | -0.25 | - | -0.60 | -0.57 | -0.45 | - | -0.33 |
| R&D Expense | 11.85M | 13.80M | 20.16M | - | 20.81M | 17.65M | 20.54M | - | 9.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 21.66M | 31.64M | 43.26M | 559.00K |
| Cost of Revenue | - | 13.46M | 12.87M | 11.81M | 215.00K |
| Gross Profit | - | 8.19M | 18.78M | 31.45M | 344.00K |
| Operating Expenses | - | 69.23M | 83.16M | 94.77M | 90.10M |
| Operating Income | - | -61.04M | -64.38M | -63.32M | -89.75M |
| EBITDA | - | -60.44M | -63.76M | -62.73M | -89.20M |
| Interest Expense | 10.80K | 56.88K | 43.31K | - | - |
| Pretax Income | - | -49.65M | -53.27M | -44.46M | -88.60M |
| Tax Provision | - | 688.00K | 956.00K | 845.00K | 11.00K |
| Net Income | - | -50.33M | -54.23M | -45.31M | -88.61M |
| Diluted EPS | - | -1.56 | -1.47 | -0.99 | -1.89 |
| R&D Expense | - | 43.55M | 56.94M | 67.88M | 67.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 130.10M | 119.45M | 202.63M | 131.44M |
| Current Assets | - | 117.01M | 103.15M | 187.37M | 118.66M |
| Cash & Equivalents | - | 66.34M | 68.79M | 121.33M | 11.28M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.11M | 290.00K | 972.00K | 0 |
| Total Liabilities | - | 103.38M | 97.45M | 68.61M | 69.14M |
| Current Liabilities | - | 26.56M | 22.34M | 16.82M | 13.61M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 539.75K | 346.00K | 117.00K | 160.00K |
| Total Equity | - | 26.71M | 21.99M | 134.02M | 62.30M |
| Shares Outstanding | - | 107.81M | 118.85M | 141.67M | 141.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -57.04M | -49.46M | -67.64M | -62.27M |
| Investing Cash Flow | - | -20.50M | 19.29M | -21.97M | -47.99M |
| Financing Cash Flow | - | 52.58M | 31.94M | 142.09M | 15.00K |
| Capital Expenditure | - | -545.00K | -56.00K | -211.00K | -55.00K |
| Free Cash Flow | - | -57.59M | -49.52M | -67.85M | -62.33M |
| Net Change in Cash | - | -24.96M | 1.77M | 52.48M | -110.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 37.8% | 59.3% | 72.7% | 61.5% |
| Operating Margin % | - | -281.9% | -203.5% | -146.4% | -16,056.0% |
| Net Margin % | - | -232.4% | -171.4% | -104.7% | -15,851.9% |
| ROE % | - | -188.4% | -246.6% | -33.8% | -142.2% |
| ROCE % | - | -59.0% | -66.3% | -34.1% | -76.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Siren, L.L.C. | 5.50% | 3.31M | $40.40M |
| 2 | TCG Crossover Management, LLC | 5.04% | 3.03M | $37.01M |
| 3 | Redmile Group, LLC | 3.60% | 2.16M | $26.41M |
| 4 | Nantahala Capital Management, LLC | 2.24% | 1.35M | $16.43M |
| 5 | Citadel Advisors Llc | 2.21% | 1.33M | $16.22M |
| 6 | Nextech Invest, Ltd. | 1.58% | 952.40K | $11.62M |
| 7 | Millennium Management Llc | 1.51% | 909.28K | $11.09M |
| 8 | Ikarian Capital, LLC | 1.38% | 830.78K | $10.14M |
| 9 | Tetragon Partners GP Ltd. | 1.27% | 764.26K | $9.32M |
| 10 | Soleus Capital Management, L.P. | 1.05% | 630.00K | $7.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLN
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbGhjM0ExZlFBV082OE1tVkphUC1wU05PeTFjX0ZQc1RMbnFpNjBKaERGaFpQd05kOXhldmR0aUtydDV2RHZvdkdBOFlEXzBHcGdIc1MzOUNFeG1CTG1DUTNBaDdYY0pJSVBrUWliRTRjMDFTQUQ5SllvRnMxaGlDdXMxdGdNSlVQQktGUk…
Silence Therapeutics Plans Underwriters' Option: Up to 15% More Depositary Shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPUDhMX1RuTlg4REpfQUhFTzhGSTRYRlNLdFdIT3laU1pBSGxZblI0M002Q2Z5c2p3c3pkOWlSSERQcmZEX0tlTE9GV1ZmQ3dVQnpYZ25WaFlBWkFXR0tGcEpzSkt2UTFKWlNpdm5wZzlock54eTBaS2djRHg5Wnl3d2Nrbmh5dnNvYWRsbW…
Silence Therapeutics stock surges as divesiran trial results fuel optimism (SLN:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPaGlGTklHX29KdUpYOGxUWmhKRDBEc1pVVm8tb2N6MkpwYzBEcGhYeWxrV003RWJVNUZqbTd0UGQ4ZF9wdktacTRNZW9YcG9VNzhCbTVHQnJ1Ym11Ylo4M3ZuR0NmN3BMZVI4MlFOWEx6RVktRERvWk9oOEJkSjhtWEthRm5WZGNWZjJCdl…
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQcUxIMDlRYnA5NDNEU2V1VVFoRWU3RHVVck55NG44NndhRHY2RGJuRjFkTDVRLXZMOTVaamp0cXZKQVFQVTdicEgzdmpETkM3ZkVpYkEwSEhBVjcwdldLcW9WVU5KU2EtN25lQVdFa2ZRZzlGMlFhbXg0enRFQmlYYk9B?oc=5" target=…
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY2F0LWpSWXFCaHc3UjBWc2owTUFDOF9Demh2MjhqVURBNVZxbGQtcl9BLXpoZmQwS2JqRXVBOWd4eEF3UUpXVXI4MVh2UDhid1ZJc19GX05PZkZiZ1I1RXIzYlNTc2U0MWtRd09KVVVPYzc1dEFTZnNoLU5fam1PWVZiWU9wVkVvaG5ZTH…
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNeDVMd2Z6c09rSHN4TE1lWGYxZi1TdmNObUNJNHdKX1lWTW9nN1FCU1QySmNYb1R6dUplcm82cm14WEVjaDlSQXFwVTYxZkQxZEpUOENRVl9jenRfRmU4LURSVFdudUJpY0pjd3BaMjlUMkRZWVR1MkxrZjVqYUZmUDd6REcyZU85YlhobH…
SLN — Frequently Asked Questions
What is the current share price of Silence Therapeutics plc (SLN)?
As of 2026-09-19 21:16 PDT, Silence Therapeutics plc (SLN) trades at $13.69 on NasdaqGM. Its 52-week range is $4.30 to $15.43.
What is the market capitalisation of SLN?
Silence Therapeutics plc (SLN) has a market capitalisation of $850.89M on NasdaqGM.
What is the P/E ratio of SLN?
SLN trades at a trailing price-to-earnings (P/E) ratio of -10.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 14.99.
What is the return on equity (ROE) of SLN?
SLN has a return on equity (ROE) of -90.41%. Its return on capital employed (ROCE) is -76.17%.
Is SLN a good stock to buy?
This page provides a data-driven analysis of Silence Therapeutics plc (SLN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.